Application of cell encapsulation for controlled delivery of biological therapeutics

Advanced Drug Delivery Reviews

Volumn 67-68, Issue , 2014, Pages 3-14

  Orive, G ^a,b   Santos, E ^a,b   Pedraz, J L ^a,b   Hernandez R M ^a,b  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

Author keywords

Cell encapsulation; Drug delivery; Microcapsule; Protein release; Scaffold

Indexed keywords

BIOMIMETICS; CYTOLOGY; DRUG DELIVERY; MICROENCAPSULATION; PROTEINS; SCAFFOLDS; STEM CELLS;

BIODEGRADABLE SCAFFOLD; BIOLOGICAL THERAPEUTICS; BIOMIMETIC SCAFFOLDS; CELL ENCAPSULATIONS; CELL MICROENCAPSULATION; LONG-TERM DRUG DELIVERY; MICROCAPSULES; PROTEIN RELEASE;

SCAFFOLDS (BIOLOGY);

ANEMIA; ANIMAL; CELL TRANSPLANTATION; DRUG DELIVERY SYSTEM; HUMAN; IMMOBILIZED CELL; MESENCHYMAL STROMA CELL; PHYSIOLOGY; PROCEDURES;

ANEMIA; ANIMALS; CELL TRANSPLANTATION; CELLS, IMMOBILIZED; DRUG DELIVERY SYSTEMS; HUMANS; MESENCHYMAL STROMAL CELLS;

EID: 84898543979     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2013.07.009     Document Type: Review

References (125)

1. Chang T.M.S. Semipermeable microcapsules. Science 1964, 146:524-525.
2. Chick W.L., Like A.A., Lauris V. Beta cell culture on synthetic capillaries: an artificial endocrine pancreas. Science 1975, 187:847-849.
3. Langer R., Vacanti J.P. Tissue engineering. Science 1993, 260:920-926.
4. Griffith L.G., Naughton G. Tissue engineering-current challenges and expanding opportunities. Science 2002, 295:1009-1014.
5. Hutmacher D.W. Scaffolds in tissue engineering bone and cartilage. Biomaterials 2000, 21:2529-2543.
6. Orive G., Hernandez R.M., Gascon A.R., Calafiore R., Chang T.M., De Vos P., Hortelano G., Hunkeler D., Lacik I., Shapiro A.M., Pedraz J.L. Cell encapsulation: promise and progress. Nat. Med. 2003, 9:104-107.
7. Orive G., Hernandez R.M., Rodriguez Gascon A., Calafiore R., Chang T.M., de Vos P., Hortelano G., Hunkeler D., Lacik I., Pedraz J.L. History, challenges and perspectives of cell microencapsulation. Trends Biotechnol. 2004, 22:87-92.
8. de Vos P., Bucko M., Gemeiner P., Navratil M., Svitel J., Faas M., Strand B.L., Skjak-Braek G., Morch Y.A., Vikartovska A., Lacik I., Kollarikova G., Orive G., Poncelet D., Pedraz J.L., Ansorge-Schumacher M.B. Multiscale requirements for bioencapsulation in medicine and biotechnology. Biomaterials 2009, 30:2559-2570.
9. Orive G., De Castro M., Ponce S., Hernández R.M., Gascón A.R., Bosch M., Alberch J., Pedraz J.L. Long-term expression of erythropoietin from myoblasts immobilized in biocompatible and neovascularized microcapsules. Mol. Ther. 2005, 12:283-289.
10. Barnett B.P., Arepally A., Karmarkar P.V., Qian D., Gilson W.D., Walczak P., Howland V., Lawler L., Lauzon C., Stuber M., Kraitchman D.L., Bulte J.W. Magnetic resonance-guided, real-time targeted delivery and imaging of magnetocapsules immunoprotecting pancreatic islet cells. Nat. Med. 2007, 13:986-991.
11. Orive G., De Castro M., Kong H.J., Hernandez R.M., Ponce S., Mooney D.J., Pedraz J.L. Bioactive cell-hydrogel microcapsules for cell-based drug delivery. J. Control. Release 2009, 135:203-210.
12. Wang N., Adams G., Buttery L., Falcone F.H., Stolnik S. Alginate encapsulation technology supports embryonic stem cells differentiation into insulin-producing cells. J. Biotechnol. 2009, 144:304-312.
13. Kauer T.M., Figueiredo J.L., Hingtgen S., Shah K. Encapsulated therapeutic stem cells implanted in the tumor resection cavity induce cell death in gliomas. Nat. Neurosci. 2011, 15:197-204.
14. Hernández R.M., Orive G., Murua A., Pedraz J.L. Microcapsules and microcarriers for in situ cell delivery. Adv. Drug Deliv. Rev. 2010, 62:711-730.
15. Bisceglie V. Über die antineoplastische Immunität. Z. Krebsforsch. 1934, 40:122-140.
16. Lim F., Sun A. Microencapsulated islets as bioartificial endocrine pancreas. Science 1980, 210:908-910.
17. Vermonden T., Fedorovich N.E., van Geemen D., Alblas J., van Nostrum C.F., Dhert W.J.A., Hennink W.E. Photopolymerized thermosensitive hydrogels: synthesis, degradation, and cytocompatibility. Biomacromolecules 2008, 9:919-926.
18. Uludag H., De Vos P., Tresco P.A. Technology of mammalian cell encapsulation. Adv. Drug Deliv. Rev. 2000, 42:29-64.
19. de Vos P., Hamel A.F., Tatarkiewicz K. Considerations for successful transplantation of encapsulated pancreatic islets. Diabetologia 2002, 45:159-173.
20. Fisher J.W. Erythropoietin: physiology and pharmacology update. Exp. Biol. Med. (Maywood) 2003, 228:1-14.
21. Moritz K.M., Lim G.B., Wintour E.M. Developmental regulation of erythropoietin and erythropoiesis. Am. J. Physiol. Regul. Integr. Comp. Physiol. 1997, 273:R1829-R1844.
22. Lacombe C., Mayeux P. Biology of erythropoietin. Haematologica 1998, 83:724-732.
23. Chong Z.Z., Kang J.Q., Maiese K. Angiogenesis and plasticity: role of erythropoietin in vascular systems. J. Hematother. Stem Cell Res. 2002, 11:863-871.
24. Juul S.E., Zhao Y., Dame J.B., Du Y., Hutson A.D., Christensen R.D. Origin and fate of erythropoietin in human milk. Pediatr. Res. 2000, 48:660-667.
25. Fandrey J., Bunn H.F. In vivo and in vitro regulation of erythropoietin mRNA: measurement by competitive polymerase chain reaction. Blood 1993, 81:617-623.
26. Vogt C., Pentz S., Rich I.N. A role for the macrophage in normal hemopoiesis: III. In vitro and in vivo erythropoietin gene expression in macrophages detected by in situ hybridization. Exp. Hematol. 1989, 17:391-397.
27. Conrad K.P., Benyo D.F., Westerhausen-Larsen A., Miles T.M. Expression of erythropoietin by the human placenta. FASEB J. 1996, 10:760-768.
28. Masuda S., Okano M., Yamagishi K., Nagao M., Ueda M., Sasaki R. A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. J. Biol. Chem. 1994, 269:19488-19493.
29. Bernaudin M., Bellail A., Marti H.H., Yvon A., Vivien D., Duchatelle I., Mackenzie E.T., Petit E. Neurons and astrocytes express EPO mRNA: oxygen-sensing mechanisms that involve the redox-state of the brain. Glia 2000, 30:271-278.
30. Mengozzi M., Latini R., Salio M., Sfacteria A., Piedimonte G., Gerwien J.G., Leist M., Siren A.L., Ghezzi P., Chimenti S. Increased erythropoietin production after myocardial infarction in mice. Heart 2006, 92:838-839.
31. Wright G.L., Hanlon P., Amin K., Steenbergen C., Murphy E., Arcasoy M.O. Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. FASEB J. 2004, 18:1031-1033.
32. Buemi M., Caccamo C., Nostro L., Cavallaro E., Floccari F., Grasso G. Brain and cancer: the protective role of erythropoietin. Med. Res. Rev. 2005, 25:245-259.
33. Chang Z.Y., Chiang C.H., Lu D.W., Yeh M.K. Erythropoiesis-stimulating protein delivery in providing erythropoiesis and neuroprotection. Expert Opin. Drug Deliv. 2008, 5:1313-1321.
34. Orive G., Ponce S., Hernandez R.M., Gascon A.R., Igartua M., Pedraz J.L. Biocompatibility of microcapsules for cell immobilization elaborated with different type of alginates. Biomaterials 2002, 23:3825-3831.
35. Ponce S., Orive G., Hernandez R.M., Gascon A.R., Canals J.M., Munoz M.T., Pedraz J.L. In vivo evaluation of EPO-secreting cells immobilized in different alginate-PLL microcapsules. J. Control. Release 2006, 116:28-34.
36. Murua A., Orive G., Hernandez R.M., Pedraz J.L. Xenogeneic transplantation of erythropoietin-secreting cells immobilized in microcapsules using transient immunosuppression. J. Control. Release 2009, 137:174-178.
37. Catena R., Santos E., Orive G., Hernández R.M., Pedraz J.L., Calvo A. Improvement of the monitoring and biosafety of encapsulated cells using the SFGNESTGL triple reporter system. J. Control. Release 2010, 146:93-98.
38. Santos E., Larzabal L., Calvo A., Orive G., Pedraz J.L., Hernandez R.M. Inactivation of encapsulated cells and their therapeutic effects by means of TGL triple-fusion reporter/biosafety gene. Biomaterials 2013, 34:1442-1451.
39. Acarregui A., Blanco F.J., Hernandez R.M., Pedraz Munoz J.L., Orive G. Hydrogel-based scaffolds for enclosing encapsulated therapeutic cells. Biomacromolecules 2012, 14:322-330.
40. Ptaszek L.M., Mansour M., Ruskin J.N., Chien K.R. Towards regenerative therapy for cardiac disease. Lancet 2012, 379:933-942.
41. Formigli L., Zecchi-Orlandini S., Meacci E., Bani D. Skeletal myoblasts for heart regeneration and repair: state of the art and perspectives on the mechanisms for functional cardiac benefits. Curr. Pharm. Des. 2010, 16:915-928.
42. Muller-Ehmsen J., Whittaker P., Kloner R.A., Dow J.S., Sakoda T., Long T.I., Laird P.W., Kedes L. Survival and development of neonatal rat cardiomyocytes transplanted into adult myocardium. J. Mol. Cell. Cardiol. 2002, 34:107-116.
43. Hodgson D.M., Behfar A., Zingman L.V., Kane G.C., Perez-Terzic C., Alekseev A.E., Puceat M., Terzic A. Stable benefit of embryonic stem cell therapy in myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 2004, 287:H471-H479.
44. Choi Y.S., Matsuda K., Dusting G.J., Morrison W.A., Dilley R.J. Engineering cardiac tissue in vivo from human adipose-derived stem cells. Biomaterials 2010, 31:2236-2242.
45. Paul A., Ge Y., Prakash S., Shum-Tim D. Microencapsulated stem cells for tissue repairing: implications in cell-based myocardial therapy. Regen. Med. 2009, 4:733-745.
46. Al Kindi A.H., Asenjo J.F., Ge Y., Chen G.Y., Bhathena J., Chiu R.C., Prakash S., Shum-Tim D. Microencapsulation to reduce mechanical loss of microspheres: implications in myocardial cell therapy. Eur. J. Cardiothorac. Surg. 2011, 39:241-247.
47. Tsur-Gang O., Ruvinov E., Landa N., Holbova R., Feinberg M.S., Leor J., Cohen S. The effects of peptide-based modification of alginate on left ventricular remodeling and function after myocardial infarction. Biomaterials 2009, 30:189-195.
48. Yu J., Du K.T., Fang Q., Gu Y., Mihardja S.S., Sievers R.E., Wu J.C., Lee R.J. The use of human mesenchymal stem cells encapsulated in RGD modified alginate microspheres in the repair of myocardial infarction in the rat. Biomaterials 2010, 31:7012-7020.
49. Gomez-Mauricio R.G., Acarregui A., Sánchez-Margallo F.M., Crisóstomo V., Gallo I., Hernández R.M., Pedraz J.L., Orive G., Martín-Cancho M.F. A preliminary approach to the repair of myocardial infarction using adipose tissue-derived stem cells encapsulated in magnetic resonance-labelled alginate microspheres in a porcine model. Eur. J. Pharm. Biopharm. 2013, 10.1016/j.ejpb.2012.11.028.
50. O'Keefe R.J., Mao J. Bone tissue engineering and regeneration: from discovery to the clinic-an overview. Tissue Eng. Part B Rev. 2011, 17:389-392.
51. Moon J.J., West J.L. Vascularization of engineered tissues: approaches to promote angio-genesis in biomaterials. Curr. Top. Med. Chem. 2008, 8:300-310.
52. Grellier M., Granja P.L., Fricain J.C., Bidarra S.J., Renard M., Bareille R., Bourget C., Amedee J., Barbosa M.A. The effect of the co-immobilization of human osteoprogenitors and endothelial cells within alginate microspheres on mineralization in a bone defect. Biomaterials 2009, 30:3271-3278.
53. Man Y., Wang P., Guo Y., Xiang L., Yang Y., Qu Y., Gong P., Deng L. Angiogenic and osteogenic potential of platelet-rich plasma and adipose-derived stem cell laden alginate microspheres. Biomaterials 2012, 33:8802-8811.
54. Intini G. The use of platelet-rich plasma in bone reconstruction therapy. Biomaterials 2009, 30:4956-4966.
55. Ulrich-Vinther M., Maloney M.D., Schwarz E.M., Rosier R., O'Keefe R.J. Articular cartilage biology. J. Am. Acad. Orthop. Surg. 2003, 11:421-430.
56. Magne D., Vinatier C., Julien M., Weiss P., Guicheux J. Mesenchymal stem cell therapy to rebuild cartilage. Trends Mol. Med. 2005, 11:519-526.
57. Dashtdar H., Rothan H.A., Tay T., Ahmad R.E., Ali R., Tay L.X., Chong P.P., Kamarul T. A preliminary study comparing the use of allogenic chondrogenic pre-differentiated and undifferentiated mesenchymal stem cells for the repair of full thickness articular cartilage defects in rabbits. J. Orthop. Res. 2011, 29:1336-1342.
58. Shanbhag M.S., Lathia J.D., Mughal M.R., Francis N.L., Pashos N., Mattson M.P., Wheatley M.A. Neural progenitor cells grown on hydrogel surfaces respond to the product of the transgene of encapsulated genetically engineered fibroblasts. Biomacromolecules 2010, 11:2936-2943.
59. Garcia P., Youssef I., Utvik J.K., Florent-Bechard S., Barthelemy V., Malaplate-Armand C., Kriem B., Stenger C., Koziel V., Olivier J.L., Escanye M.C., Hanse M., Allouche A., Desbene C., Yen F.T., Bjerkvig R., Oster T., Niclou S.P., Pillot T. Ciliary neurotrophic factor cell-based delivery prevents synaptic impairment and improves memory in mouse models of Alzheimer's disease. J. Neurosci. 2010, 30:7516-7527.
60. Grandoso L., Ponce S., Manuel I., Arrue A., Ruiz-Ortega J.A., Ulibarri I., Orive G., Hernandez R.M., Rodriguez A., Rodriguez-Puertas R., Zumarraga M., Linazasoro G., Pedraz J.L., Ugedo L. Long-term survival of encapsulated GDNF secreting cells implanted within the striatum of parkinsonized rats. Int. J. Pharm. 2007, 343:69-78.
61. Perry T., Lahiri D.K., Sambamurti K., Chen D., Mattson M.P., Egan J.M., Greig N.H. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J. Neurosci. Res. 2003, 72:603-612.
62. Heile A.M., Wallrapp C., Klinge P.M., Samii A., Kassem M., Silverberg G., Brinker T. Cerebral transplantation of encapsulated mesenchymal stem cells improves cellular pathology after experimental traumatic brain injury. Neurosci. Lett. 2009, 463:176-181.
63. GLP-1 Cell Beads® for the Treatment of Stroke Patients With Spaceoccupying Intracerebral Hemorrhage http://clinicaltrials.gov/ct2/show/NCT01298830.
64. Heile A., Brinker T. Clinical translation of stem cell therapy in traumatic brain injury: the potential of encapsulated mesenchymal cell biodelivery of glucagon-like peptide-1. Dialogues Clin. Neurosci. 2011, 13:279-286.
65. Klinge P.M., Harmening K., Miller M.C., Heile A., Wallrapp C., Geigle P., Brinker T. Encapsulated native and glucagon-like peptide-1 transfected human mesenchymal stem cells in a transgenic mouse model of Alzheimer's disease. Neurosci. Lett. 2011, 497:6-10.
66. Knippenberg S., Thau N., Dengler R., Brinker T., Petri S. Intracerebroventricular injection of encapsulated human mesenchymal cells producing glucagon-like peptide 1 prolongs survival in a mouse model of ALS. PLoS One 2012, 7:e36857.
67. Cvetanovic M., Patel J.M., Marti H.H., Kini A.R., Opal P. Vascular endothelial growth factor ameliorates the ataxic phenotype in a mouse model of spinocerebellar ataxia type 1. Nat. Med. 2011, 17:1445-1447.
68. Wang P., Xie Z.H., Guo Y.J., Zhao C.P., Jiang H., Song Y., Zhu Z.Y., Lai C., Xu S.L., Bi J.Z. VEGF-induced angiogenesis ameliorates the memory impairment in APP transgenic mouse model of Alzheimer's disease. Biochem. Biophys. Res. Commun. 2011, 411:620-626.
69. Zlokovic B.V. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci. 2005, 28:202-208.
70. Zlokovic B.V. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat. Rev. Neurosci. 2011, 12:723-738.
71. Spuch C., Antequera D., Portero A., Orive G., Hernandez R.M., Molina J.A., Bermejo-Pareja F., Pedraz J.L., Carro E. The effect of encapsulated VEGF-secreting cells on brain amyloid load and behavioral impairment in a mouse model of Alzheimer's disease. Biomaterials 2010, 31:5608-5618.
72. Antequera D., Portero A., Bolos M., Orive G., Hernandez R.M., Pedraz J.L., Carro E. Encapsulated VEGF-secreting cells enhance proliferation of neuronal progenitors in the hippocampus of AbetaPP/Ps1 mice. J. Alzheimers Dis. 2012, 29:187-200.
73. Kontturi L., Yliperttula M., Toivanen P., Määttä A., Määttä A., Urtti A. A laboratory-scale device for the straightforward production of uniform, small sized cell microcapsules with long-term cell viability. J. Control. Release 2011, 152:376-381.
74. Santos E., Orive G., Calvo A., Catena R., Fernández-Robredo P., Layana A.G., Hernández R.M., Pedraz J.L. Optimization of 100μm alginate-poly-l-lysine-alginate capsules for intravitreous administration. J. Control. Release 2012, 158:443-450.
75. Santos E., Hernandez R.M., Pedraz J.L., Orive G. Novel advances in the design of three-dimensional bio-scaffolds to control cell fate: translation from 2D to 3D. Trends Biotechnol. 2012, 30:331-341.
76. Kim H., Cooke M.J., Shoichet M.S. Creating permissive microenvironments for stem cell transplantation into the central nervous system. Trends Biotechnol. 2012, 30:55-63.
77. Lima A.C., Batista P., Valente T.A., Silva A.S., Correia I.J., Mano J. Novel methodology based on biomimetic superhydrophobic substrates to immobilize cells and proteins in hydrogel spheres for applications in bone regeneration. Tissue Eng. Part A 2012, 10.1089/ten.tea.2012.0249.
78. Silva G.A., Ducheyne P., Reis R.L. Materials in particulate form for tissue engineering. 1. Basic concepts. J. Tissue Eng. Regen. Med. 2007, 1:4-24.
79. Oliveira M.B., Mano J.F. Polymer-based microparticles in tissue engineering and regenerative medicine. Biotechnol. Prog. 2011, 27:897-912.
80. Moon J.J., Saik J.E., Poche R.A., Leslie-Barbick J.E., Lee S.H., Smith A.A., Dickinson M.E., West J.L. Biomimetic hydrogels with pro-angiogenic properties. Biomaterials 2010, 31:3840-3847.
81. Jeon O., Powell C., Solorio L.D., Krebs M.D., Alsberg E. Affinity-based growth factor delivery using biodegradable, photocrosslinked heparin-alginate hydrogels. J. Control. Release 2011, 154:258-266.
82. Anderson S.B., Lin C., Kuntzler D.V., Anseth K.S. The performance of human mesenchymal stem cells encapsulated in cell-degradable polymer-peptide hydrogels. Biomaterials 2011, 32:3564-3574.
83. Boontheekul T., Hill E.E., Kong H.J., Mooney D.J. Regulating myoblast phenotype through controlled gel stiffness and degradation. Tissue Eng. 2007, 13:1431-1442.
84. Jeon O., Alt D.S., Ahmed S.M., Alsberg E. The effect of oxidation on the degradation of photocrosslinkable alginate hydrogels. Biomaterials 2012, 33:3503-3514.
85. Chan G., Mooney D.J. New materials for tissue engineering: towards greater control over the biological response. Trends Biotechnol. 2008, 26:382-392.
86. Jeon O., Bouhadir K.H., Mansour J.M., Alsberg E. Photocrosslinked alginate hydrogels with tunable biodegradation rates and mechanical properties. Biomaterials 2009, 30:2724-2734.
87. Kong H.J., Alsberg E., Kaigler D., Lee K.Y., Mooney D.J. Controlling degradation of hydrogels via the size of crosslinked junctions. Adv. Mater. 2004, 16:1917-1921.
88. Boontheekul T., Kong H.J., Mooney D.J. Controlling alginate gel degradation utilizing partial oxidation and bimodal molecular weight distribution. Biomaterials 2005, 26:2455-2465.
89. Zhou H., Xu H.H.K. The fast release of stem cells from alginate-fibrin microbeads in injectable scaffolds for bone tissue engineering. Biomaterials 2011, 32:7503-7513.
90. Liu J., Zhou H., Weir M.D., Xu H.H., Chen Q., Trotman C.A. Fast-degradable microbeads encapsulating human umbilical cord stem cells in alginate for muscle tissue engineering. Tissue Eng. Part A 2012, 10.1089/ten.tea.2011.0658.
91. Tibbitt M.W., Anseth K.S. Hydrogels as extracellular matrix mimics for 3D cell culture. Biotechnol. Bioeng. 2009, 103:655-663.
92. Lutolf M.P., Lauer-Fields J.L., Schmoekel H.G., Metters A.T., Weber F.E., Fields G.B., Hubbell J.A. Synthetic matrix metalloproteinase-sensitive hydrogels for the conduction of tissue regeneration: engineering cell-invasion characteristics. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:5413-5418.
93. Lutolf M.P. Integration column: artificial ECM: expanding the cell biology toolbox in 3D. Integr. Biol. (Camb) 2009, 1:235-241.
94. Fonseca K.B., Bidarra S.J., Oliveira M.J., Granja P.L., Barrias C.C. Molecularly designed alginate hydrogels susceptible to local proteolysis as three-dimensional cellular microenvironments. Acta Biomater. 2011, 7:1674-1682.
95. Chen W., Zhou H., Weir M.D., Bao C., Xu H.H.K. Umbilical cord stem cells released from alginate-fibrin microbeads inside macroporous and biofunctionalized calcium phosphate cement for bone regeneration. Acta Biomater. 2012, 8:2297-2306.
96. Zhou H., Chen W., Weir M.D., Xu H.H. Biofunctionalized calcium phosphate cement to enhance the attachment and osteodifferentiation of stem cells released from fast-degradable alginate-fibrin microbeads. Tissue Eng. Part A 2012, 18:1583-1595.
97. Prockop D.J. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997, 276:71-74.
98. Goren A., Dahan N., Goren E., Baruch L., Machluf M. Encapsulated human mesenchymal stem cells: a unique hypoimmunogenic platform for long-term cellular therapy. FASEB J. 2010, 24:22-31.
99. Van Damme A., Thorrez L., Ma L., Vandenburgh H., Eyckmans J., Dell'Accio F., De Bari C., Luyten F., Lillicrap D., Collen D., VandenDriessche T., Chuah M.K. Efficient lentiviral transduction and improved engraftment of human bone marrow mesenchymal cells. Stem Cells 2006, 24:896-907.
100. McMahon J.M., Conroy S., Lyons M., Greiser U., O'shea C., Strappe P., Howard L., Murphy M., Barry F., O'Brien T. Gene transfer into rat mesenchymal stem cells: a comparative study of viral and nonviral vectors. Stem Cells Dev. 2006, 15:87-96.
101. Gebler A., Zabel O., Seliger B. The immunomodulatory capacity of mesenchymal stem cells. Trends Mol. Med. 2012, 18:128-134.
102. Zanotti L., Sarukhan A., Dander E., Castor M., Cibella J., Soldani C., Elisa Trovato A., Ploia C., Luca G., Calvitti M., Mancuso F., Arato I., Golemac M., Jonjic N., Biondi A., Calafiore R., Locati M., D'Amico G., Viola A. Encapsulated mesenchymal stem cells for in vivo immunomodulation. Leukemia 2012, 27:500-503.
103. Barry F.P., Murphy J.M., English K., Mahon B.P. Immunogenicity of adult mesenchymal stem cells: lessons from the fetal allograft. Stem Cells Dev. 2005, 14:252-265.
104. Yoo J.W., Irvine D.J., Discher D.E., Mitragotri S. Bio-inspired, bioengineered and biomimetic drug delivery carriers. Nat. Rev. Drug Discov. 2011, 10:521-535.
105. Studeny M., Marini F.C., Dembinski J.L., Zompetta C., Cabreira-Hansen M., Bekele B.N., Champlin R.E., Andreeff M. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J. Natl. Cancer Inst. 2004, 96:1593-1603.
106. Kedziorek D.A., Hofmann L.V., Fu Y., Gilson W.D., Cosby K.M., Kohl B., Barnett B.P., Simons B.W., Walczak P., Bulte J.W.M., Gabrielson K., Kraitchman D.L. X-ray-visible microcapsules containing mesenchymal stem cells improve hind limb perfusion in a rabbit model of peripheral arterial disease. Stem Cells 2012, 30:1286-1296.
107. Bidarra S.J., Barrias C.C., Barbosa M.A., Soares R., Granja P.L. Immobilization of human mesenchymal stem cells within RGD-grafted alginate microspheres and assessment of their angiogenic potential. Biomacromolecules 2010, 11:1956-1964.
108. Tang M., Chen W., Weir M.D., Thein-Han W., Xu H.H. Human embryonic stem cell encapsulation in alginate microbeads in macroporous calcium phosphate cement for bone tissue engineering. Acta Biomater. 2012, 8:3436-3445.
109. Rao R., Peterson A., Ceccarelli J., Putnam A., Stegemann J. Matrix composition regulates three-dimensional network formation by endothelial cells and mesenchymal stem cells in collagen/fibrin materials. Angiogenesis 2012, 15:253-264.
110. Ludwig B., Rotem A., Schmid J., Weir G.C., Colton C.K., Brendel M.D., Neufeld T., Block N.L., Yavriyants K., Steffen A., Ludwig S., Chavakis T., Reichel A., Azarov D., Zimermann B., Maimon S., Balyura M., Rozenshtein T., Shabtay N., Vardi P., Bloch K., de Vos P., Schally A.V., Bornstein S.R., Barkai U. Improvement of islet function in a bioartificial pancreas by enhanced oxygen supply and growth hormone releasing hormone agonist. Proc. Natl. Acad. Sci. 2012, 109:5022-5027.
111. Sakai S., Kawakami K. Synthesis and characterization of both ionically and enzymatically cross-linkable alginate. Acta Biomater. 2007, 3:495-501.
112. Sun J., Zhao X., Illeperuma W.R.K., Chaudhuri O., Oh K.H., Mooney D.J., Vlassak J.J., Suo Z. Highly stretchable and tough hydrogels. Nature 2012, 489:133-136.
113. Arifin D.R., Manek S., Call E., Arepally A., Bulte J.W.M. Microcapsules with intrinsic barium radiopacity for immunoprotection and X-ray/CT imaging of pancreatic islet cells. Biomaterials 2012, 33:4681-4689.
114. Wikström J., Elomaa M., Nevala L., Räikkönen J., Heljo P., Urtti A., Yliperttula M. Viability of freeze dried microencapsulated human retinal pigment epithelial cells. Eur. J. Pharm. Sci. 2012, 47:520-526.
115. Ma Y., Zhang Y., Liu Y., Chen L., Li S., Zhao W., Sun G., Li N., Wang Y., Guo X., Lv G., Ma X. investigation of alginate-ε-poly-l-lysine microcapsules for cell microencapsulation. J. Biomed. Mater. Res. A 2012, 10.1002/jbm.a.34418.
116. Jin J., Song M., Hourston D.J. Novel chitosan-based films cross-linked by genipin with improved physical properties. Biomacromolecules 2004, 5:162-168.
117. Hillberg A.L., Holmes C.A., Tabrizian M. Effect of genipin cross-linking on the cellular adhesion properties of layer-by-layer assembled polyelectrolyte films. Biomaterials 2009, 30:4463-4470.
118. Hillberg A.L., Kathirgamanathan K., Lam J.B., Law L.Y., Garkavenko O., Elliott R.B. Improving alginate-poly-l-ornithine-alginate capsule biocompatibility through genipin crosslinking. J. Biomed. Mater. Res. B Appl. Biomater. 2013, 101:258-268.
119. Paul A., Cantor A., Shum-Tim D., Prakash S. Superior cell delivery features of genipin crosslinked polymeric microcapsules: preparation, in vitro characterization and pro-angiogenic applications using human adipose stem cells. Mol. Biotechnol. 2011, 48:116-127.
120. David W.F. The role of short synthetic adhesion peptides in regenerative medicine; The debate. Biomaterials 2011, 32:4195-4197.
121. Lee K.Y., Mooney D.J. Alginate: properties and biomedical applications. Prog. Polym. Sci. 2012, 37:106-126.
122. Sommer B., Rinsch C., Payen E., Dalle B., Schneider B., Deglon N., Henri A., Beuzard Y., Aebischer P. Long-term doxycycline-regulated secretion of erythropoietin by encapsulated myoblasts. Mol. Ther. 2002, 6:155-161.
123. Zhao X., Kim J., Cezar C.A., Huebsch N., Lee K., Bouhadir K., Mooney D.J. Active scaffolds for on-demand drug and cell delivery. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:67-72.
124. Zanin M.P., Pettingill L.N., Harvey A.R., Emerich D.F., Thanos C.G., Shepherd R.K. The development of encapsulated cell technologies as therapies for neurological and sensory diseases. J. Control. Release 2012, 160:3-13.
125. He H., Luedke E., Zhang X., Yu B., Schmitt A., Grignol V., Carson W.E., Lee L.J. A nanonoporous cell-therapy device with controllable biodegradation for long-term drug release. J. Control. Release 2013, 165:226-233.